Pooled serum from women taking a combined estrogen-progestln oral contraceptive preparation caused significantly greater cell proliferation and Incorporation of 3 Hthymldine Into DNA In both human arterial smooth muscle cells and dermal flbroblasts In tissue culture than did serum from controls. A portion of this mitogenic effect appears to be related to the presence of a factor(s) that Is heat stable, nondialyzable, and contained in the lipoprotein-deficlent serum fraction. In vitro addition of varying concentrations of mestranol and norethlndrone, the two constituents of the oral contraceptive preparation taken by participants In the study, to control serum did not enhance Its mitogenlclty, suggesting that the effect observed with Intact serum was due either to a metabolite of these compounds or to the production of other growthpromoting substances during oral contraceptive treatment. Since smooth muscle cell proliferation Is an Integral feature of all atherosclerotic lesions, these findings provide some Insights applicable to understanding the pathogenesls of vascular disease associated with oral contraceptive use.
E pidemiological studies indicate that the use of oral contraceptives (OC) threatens the immunity to coronary heart disease (CHD) that females have enjoyed. It now appears that when healthy young women use these potent contraceptive steroids, their previously negligible risk of heart attack increases fourfold, 1 " 3 and the risk of both CHD and stroke 4 rises geometrically in the presence of other risk factors such as cigarette smoking, hypertension, and hypercholesterolemia. 5 While precisely how constituents of these preparations influence the pathogenesis of vascular disease in OC users is not known, there is evidence suggesting that they may accelerate atherogenesis. In one autopsy study, extensive degrees of arterial smooth muscle cell (SMC) proliferation and intimal deposition of lipid and This work was supported by Grants R01 HL16219 and HL22623 from the National Heart, Lung, and Blood Institute, National Institutes of Health, and the Pemco Insurance Company. ground substance were observed in coronary arteries from young women who experienced fatal myocardial infarctions. 6 Identical morphologic features of atherosclerosis were also described in uterine arteries of hysterectomy specimens obtained from women who had previously used OCs, 7 and at a number of sites in the arterial tree in two groups of young women who died of vascular complications of OC use. 8 ' 9 We have recently reported that serum from renal dialysis 10 and transplant patients and steroid-treated asthmatics, 11 groups of patients with a well-recognized predisposition to the accelerated development of cardiovascular disease, 12 has an enhanced capacity to stimulate the growth of human arterial SMC in tissue culture. As a consequence of this mitogenicity, we have postulated that by promoting SMC proliferation, circulating substances in these patients may be potential atherogens. Since abnormal growth of SMC plays a central role in this process and is a prominent feature of arterial lesions from OC-treated women, 6 we have performed studies to determine whether mitogens with similar properties might also be present in the serum of OC-treated women.
Methods

Tissue Culture
Human arterial smooth muscle cell cultures were grown from expiants of intima media segments of normal-appearing pieces of proximal aorta obtained from three young sudden death victims (two male, one female) and renal artery obtained from two recipients (one male, one female) removed at the time of renal transplantation. By phase contrast microscopy, the cells were observed to grow in multiple overlapping layers, and by electron microscopy they showed myofilaments and dense bodies characteristic of aortic smooth muscle cells in culture. 13 The expiants were grown in a humidified incubator (95% air, 5% CO 2 ) at 37° in 75 cm 2 (250 ml) flasks containing 10 ml of modified Dulbecco-Vogt medium based on that originally described by Eagle, containing 30% pooled human serum obtained from a group of six healthy volunteers, and supplemented with penicillin (100 U/ml); streptomycin (100 ng/ml; 20 mM Tricine-chloride, pH 7.4; 24 mM NaHCO 3 ; 1% (vol/vol) nonessential amino acids. Smooth muscle cells from the expiants from each donor were subcultured in the same medium, and used from the second to fourth subculture. Skin fibroblasts were grown in monolayer from the skin of normal infants and were maintained in culture conditions identical to those described for the smooth muscle cells. Fibroblasts were used for growth studies between the second and eighth passage. For each experiment, confluent monolayers of cells from stock flasks were dissociated with 0.01% trypsin-0.5 mM EDTA solution on Day 0, and 5 x 10 4 cells were seeded into each 35 mm Petri dish containing 1% pooled human serum.
Human Serum
Blood was obtained after an overnight fast from six healthy young women, ages 18 to 25 years, who were not cigarette smokers, who were receiving either Orthonovum or Norinyl (50 ng mestranol and 1 mg norethindrone) as oral contraceptive agents, and six control women of similar age taking no medications. Blood from all donors was obtained randomly during the menstrual cycle. After each blood sample was allowed to clot overnight in the refrigerator, serum was pooled from each group, then heated to 56°C for 30 minutes to inactivate complement, sterilized by filtration, and frozen (-10° C) until used. The standard tissue culture technique of pooling serum was employed in order to control for individual variability among donors. The mean triglyceride and cholesterol values obtained from three separate pools of sera from the contraceptive-treated women were 79 ± 9.2 mg/dl and 176 ± 5.2 mg/dl (mean ± SD) respectively; the mean concentrations of the corresponding control pools were 85 ± 9.7 triglyceride and 178 ± 4.4 mg/dl cholesterol. Results of the 125 I radioimmunoassay measurement of growth hor-mone (Kallestad Laboratories kit, Chaska, Minnesota) and insulin (Becton Dickinson Immunodiagnostics, Orangeburg, New York) in these same three pairs of pooled sera were as follows: growth hormone in OC pools 8.8 ± 2.3 ng/ml, controls 2.7 ± .76 ng/ml; immunoreactive insulin in the OC pools 9.7 ± 1.7 /lU/ml, control pools 10.6 ± 1.5 /xU/ml. Platelet Factor 4 levels measured by a modified radioimmunoassay procedure 14 in another representative pool contained the following concentrations: control 5750 ng/ml, OC 5825 ng/ml.
Llpoprotelns
Lipoprotein-deficient serum was prepared by centrifugation of serum pooled from control and contraceptive-treated women at d = 1.25 g/ml using KBr at 100,000 x g for 44 hours to isolate the bottom lipoprotein-free fraction. The lipoproteins in the top fraction were separated by tube-slicing. The bottom fraction was washed once at the same density to remove traces of lipoprotein and extensively dialyzed against 0.15 M NaCI-1.0 mM EDTA to remove the salt.
Growth Experiments
In each experiment, smooth muscle cells or fibroblasts from the same donor were plated in equal numbers (5 x 10 4 ) following trypsin treatment into dishes and maintained for 5 to 7 days in the standard growth medium to which 1% human serum (pooled from equal numbers of normal healthy male and female donors) had been added. Thereafter, the 1% serum-containing medium was replaced in individual sets of dishes with medium containing 10% serum from either oral contraceptive (mestranol 50 ng, norethindrone 1 mg) users or control women. The lipoprotein-deficient serum fraction from each group was added to an identical test system except that after the period of stationary growth an amount of this fraction from each test group equivalent to 5% of that present in whole serum was added to pairs of dishes containing 5% control serum, so that the final serum concentration in each was 10%. Dishes to be tested with each serum were grown in duplicate. The cells were fed three times a week.
After initiation of each experiment, the total number of cells was determined from the average of cell counts obtained (Coulter counter) in duplicate on each pair of plates grown in the test and control sera at each sampling point on the growth curve. Data from a given experiment were analyzed and compared with other experiments using Fisher's sign test, 15 a nonparametric statistical method which allows pairs of cell counts obtained serially throughout different growth studies to be examined as a group.
Mestranol and norethindrone, the two constituents of the oral contraceptive used by women in this study, were added in three concentrations alone after equilibration for 1 week in the stationary medium containing 1% human serum (mestranol: 0.4, 4.0, and 40 ng/ml; norethindrone: 4, 40, and 400 ng/ ml) and in combination (mestranol: 4.0 ng/ml; norethindrone: 40 ng/ml) to separate sets of dishes to which 10% serum from control women had been added. These levels were selected because the lower doses used in these experiments corresponded closely to plasma concentrations of mestranol (Goldzieher, personal communication) and norethindrone 16 observed following their administration to human subjects. Equal volumes of ethanol (20 or 100 \i\), the solvent in which these hormones were dissolved, were added similarly to dishes containing 10% serum alone. In the growth studies, cell counts were performed serially at the same intervals as described above.
DNA Synthesis
For these experiments, fibroblasts (3 x 10 4 cells/ dish) were seeded onto 35 mm Falcon Petri dishes and allowed to grow for 2 days in 2 ml of modified Dulbecco-Vogt medium containing 10% human serum, after which this medium was replaced with test medium containing either 10% OC or control serum, or control serum to which mestranol and norethindrone alone and in combination had been added as described above. After equilibration overnight, 6 \iC\ of 3 H-thymidine (15 Ci/mmole) was added to each dish and the cells allowed to incorporate the label for 2,4,8, and 24 hours. The medium then was removed and the cell layer washed with 2 ml of medium containing 2 mM unlabelled thymidine followed by one wash with 2 ml of Tris-EDTA solution (0.02 M Tris -0.2% EDTA). The cells were dissociated by treatment with 1.0 ml of 0.01% trypsin in Tris-EDTA solution for 5 minutes at 37° C. Aliquots of 0.1 ml were then removed for cell counting and radioactivity determination. The samples were dried on glass fiber paper discs and washed in sequence with 10% TCA, 95% ethanol and diethyl ether (5 ml/disc). After drying under an infrared lamp, the discs were counted in a liquid scintillation counter using 10 ml of scintillation fluid in each vial. The radioactivity was expressed as dpm/10 3 cells to correct for the variations in cell counts between dishes.
Results
Smooth muscle cells grown in serum from OC users showed significantly greater growth than that observed in dishes grown in serum from control women (figure 1). A similar pattern of growth stimulation was observed with five different SMC lines in further experiments with pooled serum from four other groups of OC users and controls in which cell counts were obtained early during the log phase of growth and after 6 and 12 days of exposure to the test sera (table 1) . When the mean cell counts of the OC and control dishes were compared at each sampling interval, the SMC counts in 28 of the 29 pairs of dishes (including seven observations in figure 1 ) grown in OC serum were greater than those found in the control dishes (Day 6, +122% ± 8%; Day 12, + 133% ± 9%; mean percent of control ± SEM; (p < 0.001, sign test). In four similarly performed growth studies with two different OC and control pools and three different lines of human dermal fibroblasts, mean cell counts obtained after 6 and 12 days were increased when examined as a group in all eight pairs of dishes grown in serum from the contraceptive-treated women (Day 6, +113% ± 6%; Day 12, + 163% ± 25%; p < 0.01, sign test; table 1).
In further experiments to assess the contribution of the serum lipoproteins to the enhanced mitogenicity observed with whole serum from OC users, growth studies were performed with the d > 1.25 "bottom" Evaluated by the sign test differences in cell counts in pairs of dishes shown for arterial smooth muscle cells to be significant at p < 0.001 and for dermal fibroblasts at p < 0.01. lipoprotein-poor fraction from each group; in these, this serum fraction from women receiving the oral contraceptive was found to promote the growth of both smooth muscle cells (p < 0.001; figure 2) and fibroblasts (table 2) . This stimulatory effect was demonstrable in nine experiments with three different SMC lines and two different OC and control serum pools (OC responses: Day 6, +170% ± 31 % of control; Day 12, +181% ± 43% of control), and in two experiments with two different fibroblast cell lines (OC responses: Day 6, +164% of control; Day 12, +115% of control). In both the SMC and fibroblast experiments with lipoprotein-poor serum, the mean cell counts on Day 6 and Day 12 were higher in all dishes exposed to OC serum than the counts obtained in control dishes.
Table 1. Cell Counts Following Exposure of Human Arterial Smooth Muscle Cells and Dermal FIbroblasts to Pools of Serum (10%) from Female Controls (C) and Women Taking the Same Oral Contraceptive Preparation (OC)
Experiment
Exposure of five different lines of fibroblasts to both intact (data not shown) and lipoprotein-deficient serum from OC users also significantly increased their incorporation of 3 H-thymidine into DNA ( figure  3, table 3 ). Here, more counts were found in fibro- Table 2 12 X X X X X X X X X X X X X X X X X X X X X X 10 5 10 s 10 5 10 5 10 5 10 s 10 4 10 5 10 5 10 5 10 4 10 4 10 4 10 4 10 5 10 5 10 4 10 4 10 5 10 5 10 5 10 s Evaluated by sign test differences in cell counts in pairs of dishes shown for arterial smooth muscle cells and dermal fibroblasts to be significant at p < 0.001 level. blasts exposed to OC serum than in serum from controls in 16 of the 17 pairs of cell counts during the 24-hour period of the study (p < 0.001, sign test). In two identical experiments with human arterial smooth muscle cells, a similar increase in 3 H-thymidine incorporation was found. When mestranol and norethindrone were added directly to the control se- Results expressed as percent of dpm/10 3 cells grown in serum from control women. Evaluated by sign test, differences in incorporation of 3 H-thymidine into DNA in pairs of dishes are significant at the p < 0.001. rum, no enhancement of growth measured directly by cell counts or 3 H-thymidine incorporation into DNA was observed in either smooth muscle cells or fibroblasts.
. Cell Counts Following Exposure Fibroblasts to the d > 1.25 g/dl Lipoproteln Controls (C) and Women Taking the Same of Human Arterial Smooth Muscle Cells and Dermal Deficient Fraction from Pools of Serum from Female Oral Contraceptive Preparation (OC)
Experiment
Discussion
In this series of experiments, pooled serum from groups of healthy young women receiving a commonly prescribed oral estrogen-progestin agent was found to accelerate the growth in tissue culture of both human arterial smooth cells and dermal fibroblasts. This enhanced growth-promoting capacity was also demonstrable in parallel studies showing an increase in DNA synthesis above the levels found with female control serum.
Our data do not distinguish whether this effect is related to the release of mitogenic factors from platelets during clotting 17 or whether it is the result of the action of other substances present in their serum. The fact that the concentrations of platelet Factor 4 (PF 4), which is simultaneously released from the platelet a-granule during clotting along with plateletderived growth factor (PDGF), were very similar suggests that the amount of this potent platelet-derived mitogen was equivalent in the OC and control pools. Interestingly, we found that some general properties of the serum mitogenic activity resemble those of PDGF; it is heat-stable, nondialyzable, and resides in the lipoprotein-poor fraction. Consequently, despite the fact that PF 4 levels in control and OC sera were similar, the possibility cannot be excluded that the observed differences in their mitogenicity may, in fact, be due to contraceptive-related increases in PDGF or the production of another growth factor.
Although the estrogenic and progestational constituents of the OC preparation used by women in this study did not enhance the mitogenicity of control serum when added to the cell culture system, they still may promote growth in vivo. For example, the apparent inability of the estrogen, mestranol, to further stimulate growth probably is due to the fact that it must undergo demethylation to manifest its tissue actions, 19 and cultured arterial smooth muscle cells and fibroblasts are unable to perform this biological transformation to any significant degree. Thus, mestranol's lack of growth stimulation and perhaps that of the progestin norethindrone also may result from the fact that neither substance is active in vitro. Their in vivo mitogenic actions also may result from the production of other growth-promoting substances such as somatomedins or insulin-like growth factors. 20 Evidence supporting this possibility is the recent report that growth of cultured cells was stimulated only by tissue extracts from estrogen-treated rats and not by the addition of estradiol in vitro. 21 This requirement for an intact animal in which to demonstrate estrogen's mitogenic effect presumably as a consequence of the production of other humoral factors may be analogous to our studies with OC serum.
Both growth hormone 22 and insulin 23 have been shown to stimulate SMC growth, one central feature of atherosclerotic lesions in OC users. 6 It seems unlikely that insulin is directly responsible for the effects we observed, since identical concentrations were observed in the controls and OC-treated groups. On the other hand, Ledet's studies 22 showing a direct relationship between growth hormone in concentrations found clinically and stimulation of SMC growth indicate that one cannot exclude the possibility that the small increase in growth hormone noted in OC users may contribute to the enhanced mitogenicity found in the OC pools.
Neither these tissue culture studies nor the available epidemiological evidence indicate whether one or both of the OC steroid constituents contribute to their atherogenicity. There is little doubt, however, that when estrogens are given to men at comparable doses to those found in OCs, disastrous consequences ensue. For example, administration of diethylstilbestrol in the well-known Prostatic Carcinoma Study 24 and high doses of conjugated estrogen in the Coronary Drug Project 25 resulted in similar striking and unanticipated increases in cardiovascular morbidity and mortality presumed to result from stimulation of thrombosis and not from progression of atherosclerosis during estrogen treatment. Because the small changes induced in a number of clotting factors by OCs 26 cannot alone account for the observed frequency of vascular complications associated with their use, it seems likely that vascular tissues also are a target organ for reproductive steroid hormones.
A number of observations support this hypothesis. First, morphologic studies showing that identical proliferative lesions were present in the arteries of young women who had died of vascular disease during pregnancy or immediately postpartum, 9 and in uterine arteries in hysterectomy specimens from asymptomatic women exposed for variable lengths of time to OCs, 7 imply that when present in high concentrations both endogenously produced hormones and the synthetic contraceptive steroids may act on vascular tissues. Further supporting evidence is the fact that saturable nuclear receptors for the sex steroids have been found in the major arteries, including the coronary circulation of subhuman primates, 27 and functional changes in arterial endothelium 28 and intimal proliferation have been observed in experimental animals treated with estrogen. 29 It seems likely that if contraceptive steroids have similar effects in humans, then their long-term administration in a continuous noncyclical mode and sustained interaction with cell receptors for native hormones could have important consequences on the arterial wall. While our data do not specify how these agents might influence atherogenesis in young women, our finding that serum from OC users has the capacity to consistently stimulate SMC growth above control levels suggests that long-term OC use may contribute to this component of lesion formation. A similar mitogenic action of OCs also may be expressed in nonvascular tissues by the increased incidence of uterine myomata, 30 endocervical hyperplasia, 31 and benign pituitary 33 and hepatic tumors 34 associated with their use.
The fact that estrogen treatment does not appear to accelerate atherogenesis in postmenopausal women may reflect the lower potency of the preparations they receive. In addition, the potential of sex steroids for eliciting specific adverse actions on vascular tissues when given in pharmacologic doses to inhibit ovulation probably varies considerably among these compounds as their effects on the plasma lipoproteins have been shown to do. 34 
